Iovance Biotherapeutics, Inc.

LSE:0JDK Stock Report

Market Cap: US$3.5b

Iovance Biotherapeutics Management

Management criteria checks 3/4

Iovance Biotherapeutics' CEO is Frederick Vogt, appointed in Jul 2017, has a tenure of 6.83 years. total yearly compensation is $5.26M, comprised of 12.4% salary and 87.6% bonuses, including company stock and options. directly owns 0.051% of the company’s shares, worth $1.77M. The average tenure of the management team and the board of directors is 3.3 years and 7.8 years respectively.

Key information

Frederick Vogt

Chief executive officer

US$5.3m

Total compensation

CEO salary percentage12.4%
CEO tenure6.8yrs
CEO ownership0.05%
Management average tenure3.3yrs
Board average tenure7.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Frederick Vogt's remuneration changed compared to Iovance Biotherapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$444m

Sep 30 2023n/an/a

-US$433m

Jun 30 2023n/an/a

-US$419m

Mar 31 2023n/an/a

-US$412m

Dec 31 2022US$5mUS$650k

-US$396m

Sep 30 2022n/an/a

-US$390m

Jun 30 2022n/an/a

-US$376m

Mar 31 2022n/an/a

-US$358m

Dec 31 2021US$8mUS$471k

-US$342m

Sep 30 2021n/an/a

-US$311m

Jun 30 2021n/an/a

-US$284m

Mar 31 2021n/an/a

-US$265m

Dec 31 2020US$3mUS$418k

-US$260m

Sep 30 2020n/an/a

-US$255m

Jun 30 2020n/an/a

-US$246m

Mar 31 2020n/an/a

-US$230m

Dec 31 2019US$2mUS$398k

-US$198m

Sep 30 2019n/an/a

-US$167m

Jun 30 2019n/an/a

-US$151m

Mar 31 2019n/an/a

-US$134m

Dec 31 2018US$514kUS$375k

-US$124m

Sep 30 2018n/an/a

-US$117m

Jun 30 2018n/an/a

-US$105m

Mar 31 2018n/an/a

-US$98m

Dec 31 2017US$860kUS$326k

-US$92m

Compensation vs Market: Frederick's total compensation ($USD5.26M) is above average for companies of similar size in the UK market ($USD2.59M).

Compensation vs Earnings: Frederick's compensation has been consistent with company performance over the past year.

CEO

Frederick Vogt (49 yo)

6.8yrs

Tenure

US$5,259,100

Compensation

Dr. Frederick G. Vogt, PhD, Esq., JD, serves as an Interim CEO & President at Iovance Biotherapeutics, Inc. since June 19, 2021. He has been the General Counsel at Iovance Biotherapeutics, Inc. since July...

Leadership Team

NamePositionTenureCompensationOwnership
Frederick Vogt
Interim CEO6.8yrsUS$5.26m0.051%
$ 1.8m
Jean-Marc Bellemin
CFO, Principal Accounting Officer & Treasurer3.4yrsUS$2.19m0.0087%
$ 304.7k
Igor Bilinsky
Chief Operating Officer3.2yrsUS$2.08m0.014%
$ 475.4k
Friedrich Graf Finckenstein
Chief Medical Officer4.8yrsUS$2.21m0.015%
$ 532.0k
Sara Pellegrino
Vice President of Investor Relations & Public Relationsno datano datano data
Tracy Winton
Senior Vice President of Human Resources2.1yrsno datano data
Howard Johnson
Chief Business Officer5.2yrsno datano data
James Ziegler
Executive Vice President of Commercialno datano datano data
Raj Puri
Executive VP of Regulatory Strategy & Translational Medicine2.2yrsno datano data
Brian Shew
Senior VP & Head of Digital and Information Technology2.1yrsno datano data
Kevin Smyth
Senior Vice President of Quality3.3yrsno datano data
Hequn Yin
Senior Vice President of Research2.1yrsno datano data

3.3yrs

Average Tenure

53.5yo

Average Age

Experienced Management: 0JDK's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mario Sznol
Member of Scientific Advisory Boardno datano datano data
Wayne Rothbaum
Independent Director7.9yrsUS$240.00k10.03%
$ 350.8m
Merrill McPeak
Independent Director12.8yrsUS$489.99k0.20%
$ 7.1m
Michael Weiser
Independent Director6.2yrsUS$737.49k0.050%
$ 1.8m
Jeffrey Weber
Member of Scientific Advisory Boardno datano datano data
Patrick Hwu
Member of Scientific Advisory Boardno datano datano data
Ryan Maynard
Independent Director9.3yrsUS$482.49k0.0027%
$ 93.7k
Iain Dukes
Independent Chairman of the Board7.8yrsUS$932.50k0.019%
$ 675.1k
James Mule
Member of Scientific Advisory Boardno datano datano data
Athena Countouriotis
Independent Director4.9yrsUS$482.49k0%
$ 0
Cassian Yee
Member of Scientific Advisory Boardno datano datano data
Daniel Powell
Member of Scientific Advisory Boardno datano datano data

7.8yrs

Average Tenure

62.5yo

Average Age

Experienced Board: 0JDK's board of directors are considered experienced (7.8 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.